The Arcady Group, LLC, a consulting company that works to enhance patient and disease management by addressing the challenges of medication non-adherence, has been awarded a grant from the Bill & Melinda Gates Foundation to continue Arcady’s activities to improve TB medication adherence and TB treatment outcomes. Under this most recent grant, the third from the Foundation, Arcady will be focused primarily on the further scaled deployment and systematic evaluation of patient-centric, highly affordable, highly scalable medication adherence-monitoring technologies for use with TB patients in high burden regions worldwide.
Since 2014, The Arcady Group has led and coordinated efforts to develop, evaluate, and deploy more patient-centric, more effective approaches to TB medication adherence enhancement and TB patient management. Over the last 4 years, several innovative, affordable, scalable adherence technologies have been developed, evaluated extensively in India and China, and approved for use by the World Health Organization (“WHO”). Under this most recent grant, The Arcady Group will collaborate with country programs and with organizations such as UNTAID and Stop TB Partnership to evaluate the few remaining questions regarding the use and impact of these technologies and approaches, to secure additional support from WHO for the use of these technologies and approaches as “standard of care,” and to deploy these technologies and approaches at global scale.
“Over the past 4 years, tremendous progress has been made in understanding the critical importance of adherence in TB, developing far more patient centric solutions to current monitoring practices, generating evidence supporting both the acceptability of these solutions with patients and the effectiveness of these solutions in enhancing TB medication adherence, and securing WHO approval as well as support from other key global health organizations. With this grant, we can now focus on the very exciting part of this multi-year project – actually getting these solutions deployed as standard of care in the treatment of TB patients in high burden regions around the world.”
Continuing, Mr. Thomas stated: “On behalf of my colleagues at The Arcady Group, and all of our great collaborators and partners these past several years, I’d like to express our appreciation for, and acknowledge the incredible support we and others have received from, the Bill & Melinda Gates Foundation since 2014. Largely through their support, an entirely new, more patient-centric, more effective way of managing TB patients has been developed, evaluated, approved, and deployed – to those in the greatest need. We are honored to have played a role in these efforts and along that incredible journey. For many, perhaps most of us, it has been the capstone and proudest achievement of our careers.”